Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer.
We conducted a phase II study of combination chemotherapy with irinotecan (CPT-11) and nedaplatin (NDP), (INP regimen), to determine the effects and toxicities in patients with extensive stage small cell lung cancer (SCLC). From March 2005 to December 2010, 60 patients with histologically or cytologically confirmed extensive SCLC were enrolled into this study. All received treatment CPT-11 at a dose of 60 mg/m² on days 1 and 8, and NDP 20 mg/m² on days 1-5, every 3-4 weeks as a cycle. Patients were treated until tumor progression or unacceptable toxicity. Main toxicities included: myelosuppression, nausea or vomiting, diarrhea, elevation of alanine aminotransferase,and bilirubin. No treatment related death occurred in this study. Thirteen patients had complete response, forty-two had partial response, three remained stable, and two had progressive disease. Median progression-free survival was 13 months (95% confidence interval: 9-17) and median overall survival was 22 months (95% confidence interval: 19-25). INP is an effective and well tolerated regimen for treatment of extensive staged SCLC.